# Eli Lilly

Source: https://onco.cc/companies/da-lilly/  
OnCo record `da-lilly` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lilly developed donanemab and is running further amyloid-antibody studies.

## Summary

Donanemab and remternetug sit on this company’s node so pipeline and approved products stay distinct.

## Fields

- Kind: Company
- Last checked: 2026-09-21
- Tags: dementia-atlas
- HQ: Indianapolis
- Type: pharma
- Website: https://www.lilly.com/

## Sources

- Lilly: https://www.lilly.com/

## Connected records

- drugs: [Donanemab](https://onco.cc/drugs/da-donanemab/), [Remternetug](https://onco.cc/drugs/da-remternetug/)
- trials: [EXPEDITION 3](https://onco.cc/trials/da-trial-expedition3/), [TRAILBLAZER-ALZ 2](https://onco.cc/trials/da-trial-trailblazer-alz2/)
- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/)

---
JSON: https://onco.cc/api/v1/entities/da-lilly.json